Raziel Therapeutics

Raziel Therapeutics Overview

Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for targeted fat reduction. The company has developed a new chemical entity that converts white adipose tissue (WAT) into brown adipose tissue (BAT) after a single injection into subcutaneous fat, potentially providing a new way to treat people who are overweight or obese. Raziels primary drug candidate is RZL-012, an injectable drug that is currently in preclinical development. RZL-012 is administered by several injections delivered in a single injection session. Once injected, RZL-012 triggers immediate fat-cell death, followed by a transient inflammatory process that lasts about a month during which necrotic fat tissue is replaced by fibrotic tissue. This results in a significant long-term, sustained shrinkage of fat tissue. The companys products are based on work by the team led by Professor Muli Ben-Sasson, who discovered a family of compounds that are able to influence the fate of fat-tissue cells (adipocytes) and convert them from WAT to BAT tissues. In November 2019, Raziel received FDA approval to develop RZL-012 as an orphan drug for Dercums disease.

Cumulative Funding Raised Over Time ($)

Latest News

Jul 15, 2025 · www.prnewswire.com

growth-positive

/PRNewswire/ -- 365mc, South Korea's leading medical institution specializing in fat reduction treatments, and Raziel Therapeutics, a global clinical-stage...

365mc, a leading South Korean medical institution specializing in fat reduction, has partnered with Raziel Therapeutics, a clinical-stage biopharmaceutical company, to advance the development of RZL-012 in South Korea. RZL-012 is an injectable treatment for focal fat reduction, currently progressing toward Phase 3 trials. The collaboration will focus on clinical and commercial strategies, leveraging 365mcs expertise and market presence. Additionally, 365mc will make a strategic investment in Raziel Therapeutics, facilitated by Yozma Group, to support global expansion. This partnership aims to set a new standard in non-invasive body contouring, combining Raziels technology with 365mcs proprietary LAMS procedure.

Product StagePartnersInvestment

Sep 22, 2020 · www.calcalistech.com

growth-positive

Double-chin reducing Israeli startup closes $74 million China licensing deal

Raziel Therapeutics has signed a major licensing deal with Chinas Fosun Pharma for milestone payments of up to $74 million. The agreement grants exclusive rights to Tianjin JuveStar Biotech, a company invested and incubated by Shanghai Fosun Pharmaceutical, to develop and commercialize Raziels RZL-012 compound in mainland China, Hong Kong, Macau, and Taiwan. RZL-012 is an injectable drug used for reducing double chins. Raziel Therapeutics will receive potential payments of $27 million before marketing approval, as well as additional potential sales milestone payments of up to $47 million and tiered royalty payments on future net sales. JuveStar will handle clinical studies, marketing, and sales, while Raziel will be responsible for manufacturing. The company has raised a total of $30 million to date.

PartnersInvestment

Dec 18, 2019 · en.globes.co.il

growth-positive

Fat disorder drug co Raziel Therapeutics raises $22m

Raziel Therapeutics, an Israeli clinical-stage pharmaceutical company, has raised $22 million in a Series C financing round led by Pontifax. The company is developing a new drug, RZL-012, for aesthetic applications and fat disorders. The funds will support the Phase 2b development of RZL-012 for submental fat reduction and Dercums Disease. Raziel Therapeutics recently received FDA approval to develop RZL-012 as an orphan drug for Dercums disease patients. The company also announced the appointment of Philippe Schaison as chairman of the board of directors.

Investment

Dec 10, 2018 · www.jpost.com

growth-positive

https://www.jpost.com/Special-Content/How-Israeli-Technology-is-Changing-Healthcare-574021

The article discusses the advancements in healthcare technology in Israel, highlighting the role of investors, startups, and entrepreneurs. It mentions Raziel Therapeutics as a pioneering company that has developed fat melting injections. The injections supposedly melt fat cells and prevent fat cells from forming. Clinical trials indicate a reduction of up to 50% in fat after the first injection. The article also mentions researchers from the Weizmann Institute of Science who have discovered a molecule that regulates the renewing of damaged heart muscle cells. Additionally, an Israeli engineer has developed a nonintrusive method for screening newborns for autism using otoacoustic emissions. These advancements demonstrate the potential for effective and efficient results in healthcare.

Investment

Nov 29, 2017 · www.timesofisrael.com

growth-positive

Israeli 'fat-melting' injection claims to help battle obesity

Raziel Therapeutics, an Israeli startup, has developed a fat-melting injection that destroys fat cells and delays their regeneration for up to nine months. The Jerusalem-based company claims that its product has a marked advantage over similar treatments. The injection is safer than surgery but needs to be part of a broader lifestyle change to be effective long-term. The company is funded by the Israel Innovation Authority, the Van Leer Technology Incubator, and Pontifax. The product is currently undergoing Phase 2a clinical testing in the US.

Investment

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

Prof. Menahem Plaut Street 10, Rehovot, Israel

Photos & Videos

No files yet

Raziel Therapeutics Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info